Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aktis Oncology Inc (AKTS)

Aktis Oncology Inc (AKTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,112,384
  • Shares Outstanding, K 53,403
  • Annual Sales, $ 27,380 K
  • Annual Income, $ -167,950 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales 166.45
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 4
  • High Estimate $-0.23
  • Low Estimate $-0.36
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.72 +39.27%
on 03/30/26
21.50 -4.65%
on 04/20/26
+2.80 (+15.82%)
since 03/20/26
3-Month
14.72 +39.27%
on 03/30/26
23.36 -12.24%
on 01/22/26
+0.10 (+0.49%)
since 01/21/26

Most Recent Stories

More News
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentations Data facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors...

AKTS : 20.50 (-1.58%)
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals...

AKTS : 20.50 (-1.58%)
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial...

AKTS : 20.50 (-1.58%)
Aktis Oncology to Present at Upcoming March Investor Conferences

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large...

AKTS : 20.50 (-1.58%)
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

U.S. FDA Fast Track designation granted to AKY-1189 1 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies...

AKTS : 20.50 (-1.58%)
Should You Buy PICS Stock After the PicPay IPO?

The Brazilian fintech company is purportedly set to trade from Jan. 29.

AKTS : 20.50 (-1.58%)
NU : 15.05 (-0.33%)
MarketBeat Week in Review – 01/12 - 01/16

Economic data helped stocks move higher as it showed that the Fed's decision on interest rates may not interrupt the bullish case for equities in 2026.

NFLX : 92.58 (-2.37%)
META : 668.84 (-0.31%)
GOOGL : 332.29 (-1.52%)
NVDA : 199.88 (-1.08%)
AAPL : 266.17 (-2.52%)
AVGO : 402.17 (+0.64%)
GLXY : 24.95 (-6.90%)
DAL : 70.22 (-1.39%)
TSM : 368.08 (+0.50%)
AKTX : 5.87 (-1.18%)
COST : 1,005.81 (+0.80%)
TSLA : 386.42 (-1.55%)
A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

SFD : 29.00 (+1.54%)
CRWV : 115.16 (-1.93%)
AKTS : 20.50 (-1.58%)
LLY : 903.02 (-1.83%)
MDLN : 47.51 (-1.55%)
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large...

AKTS : 20.50 (-1.58%)
Akoustis Technologies Enters Chapter 11 to Facilitate Strategic Sale Following Qorvo Legal Challenges

Akoustis Technologies files for Chapter 11 to facilitate a strategic sale while addressing legal issues with Qorvo.Quiver AI SummaryAkoustis Technologies, Inc. has announced that it has voluntarily filed...

AKTS : 20.50 (-1.58%)

Business Summary

Aktis Oncology Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis Oncology Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 22.99
2nd Resistance Point 22.24
1st Resistance Point 21.37
Last Price 20.50
1st Support Level 19.74
2nd Support Level 18.99
3rd Support Level 18.12

See More

52-Week High 29.16
Fibonacci 61.8% 23.64
Fibonacci 50% 21.94
Last Price 20.50
Fibonacci 38.2% 20.24
52-Week Low 14.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.